The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.

Surufatinib plus serplulimab and cisplatin/etoposide produced a 69.8% ORR in advanced extrapulmonary neuroendocrine carcinoma.

Arcotatug tavatecan improved PFS and OS vs physician’s choice in previously treated, CLDN18.2-positive advanced gastric and GEJ cancer.

Overall survival benefit of daraxonrasib vs chemotherapy extends across RAS genotypes, chemotherapy regimens, and prior treatment settings.

Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.

The FDA granted fast track designation to MC001 for pancreatic cancer.

The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.